Last reviewed · How we verify
Hepatic porphyria
Approved treatments
- Givlaari · Alnylam Pharmaceuticals
Givlaari works by binding to and silencing the messenger RNA (mRNA) that produces the enzyme aminolevulinate synthase 1 (ALAS1), which is overproduced in patients with hepatic porphyria.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hepatic porphyria patent landscape — cliff calendar, originator estates, attackable patents
- Hepatic porphyria treatment landscape brief
- Hepatic porphyria treatment updates RSS
Frequently asked questions about Hepatic porphyria
What drugs treat Hepatic porphyria?
Tracked treatments include Givlaari.
What is the treatment for Hepatic porphyria?
Standard treatment for Hepatic porphyria includes Givlaari. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hepatic porphyria patent cliff · Hepatic porphyria CI report
- Treatment: Givlaari · Alnylam Pharmaceuticals
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing